IrniCann®
Products
Information
Pre-Clinical Stage Glioblastoma
• Innovative pre-clinical stage drug targeting Glioblastoma Multiforme
(GBM) Stem Cells, one of the deadliest forms of brain cancer, with the
potential to transform treatment outcomes for this aggressive disease
• An estimated 250,000 new cases of GBM per year worldwide.1
• The preclinical studies demonstrated that IrniCan® was cytotoxic to
Glioblastoma tumor and stem cells, reducing cell viability and inducing),
which could establish a new benchmarkcaspase-dependent cell apoptosis
(or cell death in treating GBM by improving safety and efficacy profiles.2
